<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The isolated deletion of chromosome 20q [del(20q)] has been observed in both de novo and therapy-related cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The clinicopathologic features of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with isolated del(20q) are well characterized </plain></SENT>
<SENT sid="2" pm="."><plain>However, relatively little is known about therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (t-MNs) with isolated del(20q) </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we identified five cases of t-MN and 26 cases of de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with isolated del(20q) over a 10-year period </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases had a long latency interval from the treatment of the primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> to the <z:hpo ids='HP_0003674'>onset</z:hpo> of t-MN, and <z:hpo ids='HP_0000001'>all</z:hpo> were associated with frequent bone marrow <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>The del(20q) was the sole abnormality detected at the time of diagnosis of t-MN in three cases, six years prior to diagnosis in one case, and at the time of relapse of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in one case </plain></SENT>
<SENT sid="6" pm="."><plain>Three patients with <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) had a relatively indolent clinical course, whereas two patients presented with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> shortly after t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with isolated del(20q) presented frequently with <z:hpo ids='HP_0001903'>anemia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> which were associated with bone marrow <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>The median overall survival was 64 months </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases, del(20q) was present at the time of diagnosis </plain></SENT>
</text></document>